Summary of Agilon Health, Inc. Special Meeting Company Overview - **Company**: Agilon Health, Inc. (NYSE: AGL) - **Event**: Special Meeting of Stockholders - **Date**: March 17, 2026 Key Points Meeting Formalities - The meeting was called to order by Ronald A. Williams, Executive Chairman of the Board of Directors, with Denise Zamore serving as Corporate Secretary [2][3] - The meeting followed Delaware law and SEC rules, with an agenda posted on the special meeting website [4] - A quorum was confirmed with a majority of shares present either in person or by proxy [5] Proposals Presented 1. **Amendment Proposal**: - A proposal to adopt an amendment to the company's certificate of incorporation for a reverse stock split at a ratio between 1-for-5 and 1-for-25 [6] - The Board of Directors recommended a vote in favor of this proposal [7] 2. **Adjournment Proposal**: - A proposal to approve the adjournment of the special meeting to solicit additional proxies if necessary [7] - The Board of Directors also recommended a vote in favor of this proposal [7] Voting Results - Both proposals passed according to the preliminary report from the Independent Inspector of Election [8] - The amendment proposal's passage negated the need for adjournment to solicit additional proxies [9] - Final vote totals will be filed in a Form 8-K with the SEC within four business days following the meeting [9] Additional Information - The meeting was recorded and will be available on the company's special meeting website [2] - Shareholders were encouraged to email the investor relations team with any questions post-meeting [4] This summary encapsulates the essential details and outcomes of the special meeting held by Agilon Health, Inc.

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by certain officers and directors of Agilon Health, Inc. (NYSE: AGL) towards shareholders [1] Group 1: Investigation Details - The investigation focuses on whether Agilon Health insiders have acted against the interests of shareholders [1] - Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation [1] Group 2: Shareholder Rights and Options - Long-term shareholders of Agilon may seek corporate governance reforms, return of funds, court-approved financial incentives, or other benefits [1] - Shareholder involvement is emphasized as a means to improve company policies and enhance shareholder value [1] Group 3: Legal Representation - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having recovered millions for defrauded investors [1]

Core Insights - The company has initiated a significant transformation initiative aimed at improving its business operations and financial performance by 2026 [1] Group 1: Financial Performance - The company has reset its contracting, achieving an improvement of approximately 250 basis points, which translates to an incremental benefit of $125 million year-over-year [1] - An additional $500 million in incremental benefit is anticipated for 2026 from rate adjustments [2] Group 2: Strategic Initiatives - The company's BOI and clinical pathways initiatives are expected to generate benefits exceeding V28, indicating positive growth prospects [2] - Substantial incremental potential has been realized from quality initiatives, leading to higher incentives from payers for quality performance [2]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Agilon Health, Inc. and reminds investors of the March 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action filed against the company [1] Company Summary - Agilon Health, Inc. is currently facing a federal securities class action lawsuit [1] - The investigation is being led by Faruqi & Faruqi, a national securities law firm with multiple offices across the United States [1]

Summary of Agilon Health FY Conference Call (March 02, 2026) Company Overview - **Company**: Agilon Health (NYSE: AGL) - **Industry**: Healthcare Services - **Business Model**: Partnering with physician groups and health systems to support approximately 2,200 primary care physicians (PCPs) and over 500,000 Medicare Advantage (MA) members in transitioning to value-based care through a specialized platform and operational support [1][1]. Key Financial Highlights - **Fourth Quarter Results**: Cost trends increased year-over-year from mid-5% to 6.5%, driven by unique inpatient cases totaling over $6.5 million [4][4]. - **2026 EBITDA Guidance**: Aiming for break-even EBITDA, supported by: - Effective growth rate benchmark of over 9% [5][5]. - Disciplined contracting approach, impacting 80% of contracts, resulting in $125 million medical margin improvement year-over-year [6][6]. - Anticipated 40 basis points improvement in risk adjustment due to clinical pathways implemented, particularly in heart failure [7][7][8][8]. - Administrative cost improvements of $35 million [9][9]. Cost Trends and Challenges - **Inpatient and Part B Costs**: Notable increases in costs, particularly in oncology, with trends in the 10% range over the past 15-18 months [11][12]. - **Future Cost Projections**: For 2026, a gross cost trend of 7.5% and a net cost trend of 7% are anticipated, reflecting ongoing elevated cost trends [13][14]. Data and Risk Management - **Data Pipeline**: Enhanced capabilities for calculating member-level risk scores, with 85% of members on the new data pipeline, improving visibility into medical expenses and cost trends [16][17][18][18]. - **Cash Position**: Ended 2025 with a cash balance of $125 million, improved from a previous estimate of $100 million, providing flexibility for 2026 operations [20][21]. Market Dynamics and Enrollment Trends - **Medicare Advantage Enrollment**: Observed low single-digit growth, indicating potential structural slowing in the market, but long-term growth in Medicare is expected due to demographic trends [28][29]. - **Payer Relationships**: Positive partnerships with payers, with increased financial incentives for superior quality performance, reflecting a constructive negotiation environment [43][44]. Clinical Programs and Operational Efficiency - **Clinical Pathways**: Expansion of clinical programs, including COPD and dementia, alongside the existing heart failure program, aimed at reducing costs and improving patient outcomes [36][37]. - **Cost Management**: Ongoing efforts to right-size the cost structure in response to membership changes, with a focus on leveraging AI for operational efficiencies [37][38]. Future Outlook - **Transformational Path**: The company is on a path of transformation, with significant progress made in 2025 and ongoing initiatives to enhance profitability in 2026 and beyond [51][51]. - **CEO Search**: The board is actively engaged in a thorough search process for a new CEO, with both internal and external candidates being considered [50][50]. This summary encapsulates the key points discussed during the Agilon Health FY Conference Call, highlighting the company's financial performance, market dynamics, operational strategies, and future outlook.

Core Viewpoint - Rosen Law Firm is reminding investors who purchased agilon health, inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased agilon securities between February 26, 2025, and August 4, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 2, 2026 [3]. - The lawsuit alleges that defendants made false or misleading statements regarding agilon's financial guidance and the impact of strategic actions taken to reduce risk, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked highly in securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - A class action lawsuit has been filed against Agilon Health, Inc. for allegedly making false and misleading statements regarding its financial guidance and business operations during the Class Period from February 26, 2025, to August 4, 2025 [3][6]. Allegation Details - The lawsuit claims that Agilon's defendants issued guidance for 2025 that they knew or should have known was unattainable due to significant industry challenges [3]. - It is alleged that the defendants overstated the immediate positive financial impact from strategic actions taken to mitigate risks [3]. - As a result, the statements made about Agilon's business, operations, and future prospects were materially false and misleading throughout the Class Period [3]. Next Steps - Investors who purchased Agilon shares and experienced losses are encouraged to contact the law firm for more information regarding their rights and potential claims [4][6]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is March 2, 2026 [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased agilon health, inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who bought agilon securities between February 26, 2025, and August 4, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by March 2, 2026 [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [4]. Group 3: Case Allegations - The lawsuit alleges that defendants made false or misleading statements regarding agilon's financial guidance for 2025, overstated the positive impact of strategic actions, and misrepresented the company's business prospects, leading to investor damages when the truth was revealed [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased agilon health, inc. securities between February 26, 2025, and August 4, 2025, about the March 2, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought agilon securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The deadline to move the Court to serve as lead plaintiff is March 2, 2026, with the lead plaintiff representing other class members in the litigation [3]. Group 2: Case Allegations - The lawsuit alleges that defendants made false or misleading statements and failed to disclose critical information, including: 1. Reckless guidance for 2025 that was unlikely to be achieved due to known industry challenges [5]. 2. Material overstatement of the financial impact from strategic actions taken by agilon to mitigate risk [5]. 3. Overall misleading statements regarding agilon's business operations and prospects throughout the Class Period [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked highly in securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased agilon health, inc. securities between February 26, 2025, and August 4, 2025, of the March 2, 2026, deadline to become a lead plaintiff in a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased agilon securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The lawsuit alleges that defendants made false and misleading statements regarding agilon's financial guidance and the impact of strategic actions taken by the company, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action litigation [4].